Cargando…

Medical management of muscle weakness in Duchenne muscular dystrophy

INTRODUCTION: Duchenne muscular dystrophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines regarding recently approved DMD medications and alternative steroid dosing regimens. METHODS: A list of statements about use o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivera, Sarah R., Jhamb, Sumit K., Abdel-Hamid, Hoda Z., Acsadi, Gyula, Brandsema, John, Ciafaloni, Emma, Darras, Basil T., Iannaccone, Susan T., Konersman, Chamindra G., Kuntz, Nancy L., McDonald, Craig M., Parsons, Julie A., Tesi Rocha, Carolina, Zaidman, Craig M., Butterfield, Russell J., Connolly, Anne M., Mathews, Katherine D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571693/ https://www.ncbi.nlm.nih.gov/pubmed/33075081 http://dx.doi.org/10.1371/journal.pone.0240687

Ejemplares similares

Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Connolly, Anne M., et al.
Publicado: (2023)

Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
por: Finkel, Richard S., et al.
Publicado: (2023)

Electrical impedance myography for reducing sample size in Duchenne muscular dystrophy trials
por: Leitner, Melanie L., et al.
Publicado: (2019)

Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Clemens, Paula R., et al.
Publicado: (2022)

Characteristics of Clinical Trial Participants with Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)
por: Mathews, Katherine D., et al.
Publicado: (2021)

Evaluating a Stone of Hope: ICER’s 2019 Review of Treatments for Duchenne Muscular Dystrophy
por: Brandsema, John Frederick
Publicado: (2020)

A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
por: Allen, Hugh D., et al.
Publicado: (2013)

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
por: McDonald, Craig M., et al.
Publicado: (2021)

Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab
por: Sherlock, Sarah P., et al.
Publicado: (2022)

Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study
por: Clemens, Paula R., et al.
Publicado: (2023)

Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial
por: Muntoni, Francesco, et al.
Publicado: (2022)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies
por: Ramani, Praveen Kumar, et al.
Publicado: (2023)

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
por: Clemens, Paula R., et al.
Publicado: (2020)

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials
por: McDonald, Craig M., et al.
Publicado: (2019)

Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
por: Biggar, W. Douglas, et al.
Publicado: (2022)

Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Novel autosomal dominant TNNT1 mutation causing nemaline myopathy
por: Konersman, Chamindra G., et al.
Publicado: (2017)

Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy
por: Goedeker, Natalie L., et al.
Publicado: (2023)

Deflazacort for the treatment of Duchenne Dystrophy: A systematic review
por: Campbell, Craig, et al.
Publicado: (2003)

Myocardial strain imaging in Duchenne muscular dystrophy
por: Earl, Conner C., et al.
Publicado: (2022)

Muscle weakness has a limited effect on motor control of gait in Duchenne muscular dystrophy
por: Vandekerckhove, Ines, et al.
Publicado: (2020)

Don’t forget the trunk in Duchenne muscular dystrophy patients: more muscle weakness and compensation than expected
por: Peeters, L. H. C., et al.
Publicado: (2019)

Spinal muscular atrophy, pediatric virology and gene therapy: A challenge of modern weakness and hope
por: Darras, Basil T., et al.
Publicado: (2018)

Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy
por: Mann, Joshua R., et al.
Publicado: (2023)

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage
por: Klimchak, Alexa C, et al.
Publicado: (2021)

Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy
por: McDonald, Craig M., et al.
Publicado: (2018)

Health-Related Quality of Life in Children with DuchenneMuscular Dystrophy: A Review
por: Wei, Yi, et al.
Publicado: (2015)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data
por: Szabo, Shelagh M., et al.
Publicado: (2022)

Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy
por: Fang, Yuan, et al.
Publicado: (2023)

Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy
por: Sherlock, Sarah P., et al.
Publicado: (2022)

Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy
por: Timpani, Cara A., et al.
Publicado: (2020)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy
por: Buyse, Gunnar M., et al.
Publicado: (2016)

Trained immunity as a potential target for therapeutic immunomodulation in Duchenne muscular dystrophy
por: Petrof, Basil J., et al.
Publicado: (2023)

Influence of β(2) adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy
por: Kelley, Eli F., et al.
Publicado: (2019)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

Newborn screening for Duchenne muscular dystrophy‐early detection and diagnostic algorithm for female carriers of Duchenne muscular dystrophy
por: Gruber, Dorota, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l9lm4uaklghi6fh5e3gelqum1b